Storia in 17 fonti

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

Raccontata da

france24.com+5 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo20 h fa

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

originale

Timeline cronologica

martedì 25 agosto 2026·letemps.ch
L’Agence américaine du médicament approuve le Rasonque, traitement très prometteur contre le cancer du pancréas - Le Temps
Le médicament utilisant le daraxonrasib vient d’être autorisé sur le sol américain, pour un coût de traitement d’environ de 40 000 dollars par mois. Des essais cliniques…
mercoledì 26 agosto 2026·biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Confronto fonti

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Timeline cronologica

L’Agence américaine du médicament approuve le Rasonque, traitement très prometteur contre le cancer du pancréas - Le Temps

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

FDA approves new drug Rasonque to treat advanced pancreatic cancer

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival — and is set to $475,000 a year

Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet | Fortune

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

FDA approves ‘game-changing’ pancreatic cancer drug

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet | Fortune

FDA approves new drug Rasonque to treat advanced pancreatic cancer

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

FDA approves breakthrough drug for metastatic pancreatic cancer: 'A real revolution'

Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival — and is set to $475,000 a year

A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance

FDA approves pancreatic cancer drug that nearly doubles survival time

FDA approves landmark pancreatic cancer drug